Evaluating boron neutron capture therapy as a potential treatment for unresectable gastrointestinal stromal tumors
Authors:
- 25 June 2025
- journal article
- research article
- Published by Springer Nature in Gastric Cancer
- Vol. 28 (5) , 924-934
Abstract
Background Boron neutron capture therapy selectively delivers the boron isotope 10B to tumors, where neutron irradiation induces a nuclear reaction that generates particle radiation, eradicating cancer cells. Imatinib and other drug therapies remain standard treatments for recurrent and unresectable gastrointestinal stromal tumors; however, their efficacy is limited by drug resistance. Therefore, developing novel therapeutic strategies for unresectable gastrointestinal stromal tumors is essential. This study aimed to investigate the therapeutic potential of boron neutron capture therapy for recurrent and unresectable gastrointestinal stromal tumors. Methods The GIST-T1 cell line and its imatinib-resistant variant (GIST-T1/IM-R) were utilized to assess boronophenylalanine uptake and evaluate boron neutron capture therapy efficacy in both in vitro and in vivo models. Results Boronophenylalanine was substantially incorporated into GIST-T1 and GIST-T1/IM-R cells. Boron neutron capture therapy significantly reduced survival fractions in both cell lines compared to neutron irradiation alone. In the GIST-T1 mouse model, high boronophenylalanine uptake was observed 3 h post-administration, resulting in significant tumor growth suppression following boron neutron capture therapy. Elevated expression of cleaved PARP, Caspase-3, Caspase-8, and γH2AX significantly increased in GIST-T1 tumors post-boron neutron capture therapy. Conclusions The results indicate that boron neutron capture therapy suppresses tumor growth by inducing extrinsic apoptosis through severe DNA damage. This study suggests that boron neutron capture therapy is a promising alternative treatment for gastrointestinal stromal tumors, particularly for cases exhibiting resistance to conventional therapies. Graphical abstractKeywords
Funding Information
- Japan Society for the Promotion of Science (21H02992)
- Medtronic Japan
- Japan Agency for Medical Research and Development (JP25ama121052)
- Japan Agency for Medical Research and Development (JP25ama121054)
This publication has 40 references indexed in Scilit:
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001
- Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- The Radiation Biology of Boron Neutron Capture TherapyRadiation Research, 1999
- FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling ComplexCell, 1996
- Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell DeathCell, 1996
- Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosisNature, 1995
- CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme.Journal of Biological Chemistry, 1994
- Role of poly(ADP-ribose) formation in DNA repairNature, 1992
- SELECTIVE DELIVERY OF BORON BY THE MELANIN PRECURSOR ANALOG PARA-BORONOPHENYLALANINE TO TUMORS OTHER THAN MELANOMA1990
- TREATMENT OF MALIGNANT MELANOMA BY SINGLE THERMAL NEUTRON CAPTURE THERAPY WITH MELANOMA-SEEKING 10B-COMPOUNDThe Lancet, 1989